1,4-利-1,2,3-二醇新利格南-切尔科克西布混合物抑制了由齐莫桑诱导的实验性关节炎
Josyelen L Felipe1, Iluska S Bonfá1, Paloma K M B Lossavaro1
1Laboratory of Pharmacology and Inflammation, Faculty of Pharmaceutical Sciences, Food and Nutrition, Federal University of Mato Grosso Do Sul, UFMS, Campo Grande, MS, 79070-900, Brazil.
Inflammopharmacology
|October 8, 2023
概括
新的混合三醇类似物L15和L18在试验性关节炎模型中显示出显著的抗炎作用. 这些化合物减少关节胀,软骨损伤和巨细胞介导的炎症,为类风湿性关节炎 (RA) 提供潜在的治疗方法.
科学领域:
- 药用化学 医学化学
- 免疫学 免疫学 免疫学
- 类风湿病学 类风湿病学
背景情况:
- 类风湿性关节炎 (RA) 是一种导致软骨损伤的慢性自身免疫性疾病,通常用抗炎药物治疗,有胃肠道和心血管副作用的风险.
- 以前的研究表明,混合三醇类似物 (neolignan-celecoxib) 与硫胺 (L15) 或碳酸 (L18) 替代物具有抗炎活性,并减少血小板激活,而不会诱导胃.
研究的目的:
- 在实验性关节炎模型中评估L15和L18的抗炎疗效.
- 评估L15和L18对对RA病变发生相关的巨细胞功能的影响.
主要方法:
- 试验性关节炎模型在动物.
- 评估机械过敏症,关节,白细胞透和软骨损伤.
- 评估巨细胞毒性,扩散,细胞活性,氧化 (NO) 和过氧化的产生.
主要成果:
- L15和L18显著减少了机械过敏症,关节和白细胞流入关节.
- 组织学分析显示,L15和L18减轻了软骨损伤,并防止了类风湿性形的形成.
- 同类药物没有表现出细胞毒性,抑制了巨细胞的NO和过氧化生产,L15也降低了细胞形成.
结论:
- 在实验模型中,L15和L18表现出强大的抗炎和抗关节炎作用.
- 这些新型类似物显示出良好的安全性,无细胞毒性,并最大限度地减少与传统抗炎药物相关的副作用.
- L15和L18代表了有前途的治疗原型,用于管理慢性炎症状况,如类风湿性关节炎.
相关概念视频
01:19Antiasthma Drugs: Leukotriene Modifiers
330
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
330
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
154
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
154
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
178
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
178